Low-cost-investment anti-cancer drug MG preparation and preparation process thereof
By selecting appropriate raw materials and processes in anti-cancer drug preparations, the problems of unstable quality and high cost of drugs caused by unscientific prescription design in the prior art are solved, low-cost investment and efficient preparation are achieved, and the stability of drugs is ensured. Sexual and economic benefits.
Patent Information
- Application Number
- CN202310527217.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-11
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prescription process design of existing anti-cancer drug preparations is not scientific enough, resulting in unstable drug quality, increasing R&D costs and limiting profit margins.
Using low-cost investment in anti-cancer drug MG preparations, including F1-F3 prescriptions, select raw materials such as lactose, microcrystalline cellulose, sodium hydroxymethyl starch, silica and magnesium stearate, and use sieves, mixing, Filling and wet and dry granulation processes, optimize the preparation process to reduce costs.
While ensuring the efficacy of the drug, the prescription process is optimized, the R&D costs are reduced, and the production process is ensured smoothly, improving the stability of the drug quality.
Smart Images

Figure BDA0004223152520000051 
Figure BDA0004223152520000061 
Figure BDA0004223152520000071
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug preparation, in particular to a low-cost anticancer drug MG preparation and a preparation process thereof. Background Art
[0002] In recent years, the anti-cancer pharmaceutical industry has developed rapidly, with more and more new technologies and advanced equipment being put into use, which has improved its drug process level. However, there are still some shortcomings. In order to shorten the approval time, some drugs only apply for simple prescription processes when they are applied for, which leads to actual production difficulties. Some pharmaceutical companies do not file data for prescription processes during the research and development stage, which may greatly affect the efficacy of anti-cancer drugs after they are produced, greatly increase research and development costs, and even the prescription process of the developed anti-cancer drug preparations cannot be carried out smoothly during the production process. These immature preparation studies, due to the lack of scientific design of prescriptions and processes, will lead to changes in drug quality, greatly increase research and development costs, and result in not having a lot of profit margins, so pharmaceutical companies find it difficult to obtain economic benefits. Summary of the invention
[0003] In view of the deficiencies of the prior art, the present invention provides a low-cost anticancer drug MG preparation and a preparation process thereof, which solves the problem that the traditional process greatly increases the research and development costs, resulting in a lack of profit margins.
[0004] To achieve the above objectives, the present invention is implemented by the following technical scheme: a low-cost anticancer drug MG preparation, including three prescriptions F1-F3, wherein the F1 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 24.39%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00% and magnesium stearate 1.00%;
[0005] The F2 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 21.39%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00%, hydroxypropyl cellulose 3.00% and magnesium stearate 1.00%;
[0006] The F3 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 23.89%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00% and magnesium stearate 1.5%.
[0007] Preferably, a low-cost preparation process of an anticancer drug MG preparation, the preparation process of the F1 formulation, comprises the following steps:
[0008] S1. Weighing and sieving
[0009] After weighing the raw materials according to the proportion, first MG raw material drug and silicon dioxide are sieved through a 50-mesh sieve together, then lactose, microcrystalline cellulose and sodium hydroxymethyl starch are sieved through a 50-mesh sieve in sequence, and magnesium stearate is sieved through a 30-mesh sieve alone;
[0010] S2. Material mixing
[0011] The sieved MG raw material drug, lactose, microcrystalline cellulose, sodium hydroxymethyl starch and silicon dioxide were placed in a No. 7 ziplock bag and manually shaken for 5 min. Then, the sieved magnesium stearate was added to the ziplock bag and manually shaken again for 3 min.
[0012] S3. Filling
[0013] The mixed powder was filled into hollow gelatin capsules and weighed using an analytical scale. The total weight of the capsules was controlled at 456 mg ± 5%.
[0014] Preferably, the preparation process of the F2 and F3 formulations comprises the following steps:
[0015] S1. Weighing and sieving
[0016] After weighing the F2 and F3 raw materials according to the proportion, the MG raw material drug and silicon dioxide were sieved through a 50-mesh sieve, and then lactose, microcrystalline cellulose, hydroxypropyl cellulose and sodium hydroxymethyl starch were sieved through a 50-mesh sieve in sequence, and magnesium stearate was sieved through a 30-mesh sieve alone;
[0017] S2. Wet granulation after mixing
[0018] The sieved materials of F2 and F3 were placed in No. 7 ziplock bags and manually shaken for 5 min to obtain F2 main mixed powder and F3 main mixed powder. The F2 main mixed powder was then placed in a beaker, and the prescribed amount of binder solution was manually dripped into the beaker while stirring. After continuous stirring to form granules, the granules after wet granulation were wet granulated, and the size of the wet granulation sieve was 18 meshes;
[0019] S3. Drying
[0020] The wet granules were spread on a tray and placed in an oven for drying at 60°C. During the drying period, the moisture content of the granules was tested using a rapid moisture tester until the moisture content dropped below 1%. After the moisture content dropped below 1%, the F2 granules were dry granulated using a 24-mesh sieve.
[0021] S4. Dry granulation
[0022] The F3 main mixed powder prepared in S2 was placed in a dry granulator, and dry granulated at a roller pressure of 30 bar, a roller speed of 5 rpm, and a granulation speed of 100 rpm. After granulation, the powder was sieved using a sieve with an aperture of 1.0 mm.
[0023] S5. Total Mixing
[0024] The granules prepared by the wet method and the granules prepared by the dry method were respectively filled into hollow gelatin capsules and weighed using an analytical scale. The total weight of the capsules was controlled at 456 mg ± 5%.
[0025] The present invention provides a low-cost anticancer drug MG preparation and its preparation process. It has the following beneficial effects:
[0026] 1. The present invention selects lactose and microcrystalline cellulose with good fluidity as fillers of MG, sodium carboxymethyl starch as a disintegrant, silicon dioxide as a retention aid, and magnesium stearate as a lubricant, thereby optimizing the preparation process of the prescription while ensuring the efficacy, reducing the research and development cost, and ensuring the smooth progress of the prescription process in the production process. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 is the dissolution curve diagram of F1, F2 and F3 of the present invention;
[0028] Figure 2 It is the dissolution curve diagram of F2, F4 and F5 of the present invention;
[0029] Figure 3 It is the dissolution curve diagram of F4, F6 and F7 of the present invention. DETAILED DESCRIPTION
[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0031] Embodiment 1:
[0032] like Figure 1 As shown, the embodiment of the present invention provides a low-cost anticancer drug MG preparation, including three prescriptions F1-F3, and the F1 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 24.39%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00% and magnesium stearate 1.00%;
[0033] The F2 prescription included the following percentage raw materials: MG raw drug substance 20.83%, lactose 48.78%, microcrystalline cellulose 21.39%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00%, hydroxypropyl cellulose 3.00%, and magnesium stearate 1.00%;
[0034] The F3 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 23.89%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00% and magnesium stearate 1.5%.
[0035] The preparation process of the F1 prescription includes the following steps:
[0036] S1. Weighing and sieving
[0037] After weighing the raw materials according to the proportion, first MG raw material drug and silicon dioxide are sieved through a 50-mesh sieve together, then lactose, microcrystalline cellulose and sodium hydroxymethyl starch are sieved through a 50-mesh sieve in sequence, and magnesium stearate is sieved through a 30-mesh sieve alone;
[0038] S2. Material mixing
[0039] The sieved MG raw material drug, lactose, microcrystalline cellulose, sodium hydroxymethyl starch and silicon dioxide were placed in a No. 7 ziplock bag and manually shaken for 5 min. Then, the sieved magnesium stearate was added to the ziplock bag and manually shaken again for 3 min.
[0040] S3. Filling
[0041] The mixed powder was filled into hollow gelatin capsules and weighed using an analytical level. The total weight of the capsules was controlled at 456 mg.
[0042] The preparation process of F2 and F3 formulations includes the following steps:
[0043] S1. Weighing and sieving
[0044] After weighing the F2 and F3 raw materials according to the proportion, the MG raw material drug and silicon dioxide were sieved through a 50-mesh sieve, and then lactose, microcrystalline cellulose, hydroxypropyl cellulose and sodium hydroxymethyl starch were sieved through a 50-mesh sieve in sequence, and magnesium stearate was sieved through a 30-mesh sieve alone;
[0045] S2. Wet granulation after mixing
[0046] The sieved materials of F2 and F3 were placed in No. 7 ziplock bags and manually shaken for 5 min to obtain F2 main mixed powder and F3 main mixed powder. The F2 main mixed powder was then placed in a beaker, and the prescribed amount of binder solution was manually dripped into the beaker while stirring. After continuous stirring to form granules, the granules after wet granulation were wet granulated, and the size of the wet granulation sieve was 18 meshes;
[0047] S3. Drying
[0048] The wet granules were spread on a tray and placed in an oven for drying at 60°C. During the drying period, the moisture content of the granules was tested using a rapid moisture tester until the moisture content dropped below 1%. After the moisture content dropped below 1%, the F2 granules were dry granulated using a 24-mesh sieve.
[0049] S4. Dry granulation
[0050] The F3 main mixed powder prepared in S2 was placed in a dry granulator, and dry granulated at a roller pressure of 30 bar, a roller speed of 5 rpm, and a granulation speed of 100 rpm. After granulation, the powder was sieved using a sieve with an aperture of 1.0 mm.
[0051] S5. Total Mixing
[0052] The granules prepared by the wet method and the granules prepared by the dry method were filled into hollow gelatin capsules respectively and weighed using an analytical level. The total weight of the capsules was controlled at 456 mg.
[0053] The dissolution tester was used to test the dissolution of the products of the F1-F3 formulations. The speed of the tester was 75 rpm, the dissolution medium was 0.1N HCl + 1% surfactant, and samples were taken at 5, 10, 15, 30, 45, 60 and 75 min. The comparison of the dissolution results of F1-F3 is shown in the following table:
[0054]
[0055]
[0056] According to the dissolution results, the dissolution rate of the preparation product (F1) using the direct filling process was significantly higher than that of the preparation products using the wet granulation process (F2) and the dry granulation process (F3) before 30 minutes. However, after 30 minutes, there was no significant difference in dissolution release among the three. Considering that the wet granulation process is superior to the other two processes in terms of mixing uniformity and material fluidity, the subsequent prescription uses the wet granulation process.
[0057] Embodiment 2:
[0058] like Figure 2 As shown, the embodiments of the present invention provide the effects of different disintegrants on the dissolution and release of the formulation product. Based on the F2 formulation, a formulation of sodium carboxymethyl starch containing 5% of the F4 formulation and 7% of the F5 formulation was prepared, and the dissolution and release of the formulation with a disintegrant dosage between 3% and 7% was investigated.
[0059] The F4 prescription included the following percentage raw materials: MG raw drug substance 20.83%, lactose 48.78%, microcrystalline cellulose 19.39%, sodium hydroxymethyl starch 5%, silicon dioxide 2.00%, hydroxypropyl cellulose 3.00%, and magnesium stearate 1.00%;
[0060] The F5 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 17.39%, sodium hydroxymethyl starch 7%, silicon dioxide 2.00%, hydroxypropyl cellulose 3.00% and magnesium stearate 1.00%.
[0061] The preparation process of F4 and F5 formulations includes the following steps:
[0062] S1. Weigh the raw materials of F4 and F5 according to the prescription amount, first sieve the MG raw material drug and silicon dioxide together through a 50-mesh sieve, then sieve lactose, microcrystalline cellulose, and sodium hydroxymethyl cellulose through the same 50-mesh sieve in sequence, and sieve magnesium stearate through a 30-mesh sieve alone;
[0063] S2. Except for magnesium stearate, the sieved F4 and F5 excipients were placed in No. 7 ziplock bags and manually shaken for 5 min;
[0064] S3. Put the F4 main mixed powder into a beaker, and manually drip the prescribed amount of binder solution while stirring. Stir to form granules. Determine whether to continue adding rehydration according to the granulation situation. Wet granulate the granules after wet granulation. The size of the wet granulation sieve is 18 mesh. F5 is granulated in the same way. Spread the granules of F4 and F5 after wet granulation on a tray, put them in an oven, set the drying temperature to 60°C, and use a rapid moisture meter to detect the moisture content of the granules to reduce the moisture content to below 1%;
[0065] S4. The sieved magnesium stearate, F4 and F5 granules were placed in a No. 7 ziplock bag and mixed manually for 3 min;
[0066] S5. The granules prepared from F4 and F5 were filled into capsule shells, respectively, and weighed using analytical level, and the drug weight range was 456 mg + _ 5%.
[0067] The dissolution tester was used to test the dissolution of the products of F4 and F5 respectively. The speed of the tester was 75 rpm, the dissolution medium was 0.1N HCl+1% surfactant, and samples were taken at 5, 10, 15, 30, 45, 60 and 75 min. The comparison of the dissolution results of F2, F4 and F5 is shown in the following table:
[0068]
[0069]
[0070] According to the dissolution results, it can be concluded that the dissolution rate of the preparation product (F2) containing 3% disintegrant was slightly lower than that of the preparation products containing 5% (F4) and 7% (F5) before 30 minutes; there was no difference in the dissolution release between the preparations containing 5% and 7% disintegrant, and the preparation containing 5% disintegrant (F4) was selected for further investigation.
[0071] Embodiment three:
[0072] like Figure 3 As shown, the embodiment of the present invention provides the effect of different filler dosages on the dissolution and release of the preparation product. The filler ratio used in the F4 prescription is lactose: microcrystalline cellulose = 2:1. Lactose is a soluble excipient, and microcrystalline cellulose is an insoluble excipient. Therefore, in the F6 prescription, lactose: microcrystalline cellulose = 1:1, and in the F7 prescription, lactose: microcrystalline cellulose = 1:3. The prescriptions with different ratios of two fillers are used to examine the effect of different ratios of soluble excipients and insoluble excipients on dissolution.
[0073] The F6 prescription included the following percentage raw materials: MG raw drug substance 20.83%, lactose 34.08%, microcrystalline cellulose 34.08%, sodium hydroxymethyl starch 5%, silicon dioxide 2.00%, hydroxypropyl cellulose 3.00%, and magnesium stearate 1.00%;
[0074] The F7 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 19.39%, microcrystalline cellulose 48.78%, sodium hydroxymethyl starch 5%, silicon dioxide 2.00%, hydroxypropyl cellulose 3.00% and magnesium stearate 1.00%.
[0075] The preparation process of F6 and F7 formulations includes the following steps:
[0076] S1. Weigh the raw materials of F6 and F7 according to the prescription amount, first sieve the MG raw material drug and silicon dioxide together through a 50-mesh sieve, then sieve lactose, microcrystalline cellulose, and sodium hydroxymethyl cellulose through the same 50-mesh sieve in sequence, and sieve magnesium stearate through a 30-mesh sieve alone;
[0077] S2. Except for magnesium stearate, the sieved F6 and F7 excipients were placed in No. 7 ziplock bags and manually shaken for 5 min;
[0078] S3. Put the F6 main mixed powder into a beaker, and manually drip the prescribed amount of binder solution while stirring. Stir to form granules. Determine whether to continue adding rehydration according to the granulation situation. Wet granulate the granules after wet granulation. The size of the wet granulation sieve is 18 mesh. F7 is granulated in the same way. Spread the granules of F6 and F7 after wet granulation on a tray, put them in an oven, set the drying temperature to 60°C, and use a rapid moisture meter to detect the moisture of the granules to reduce the moisture to below 1%;
[0079] S4. The sieved magnesium stearate was placed in a No. 7 ziplock bag together with the F6 and F7 granules and mixed manually for 3 min;
[0080] S5. Fill the drug granules prepared from F6 and F7 into capsule shells respectively and weigh them using analytical level. The drug weight range is 456 mg ± 5%.
[0081] The dissolution tester was used to test the dissolution of the products of F6 and F7 respectively. The speed of the tester was 75 rpm, the dissolution medium was 0.1N HCl+1% surfactant, and samples were taken at 5, 10, 15, 30, 45, 60 and 75 min. The comparison of the dissolution results of F4, F6 and F7 is shown in the following table:
[0082]
[0083] Based on the dissolution results, it can be concluded that the formulation with more soluble filler-lactose has a faster dissolution rate before 30 minutes.
[0084] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A low-cost anticancer drug MG preparation, characterized in that: It includes three prescriptions F1-F3, wherein the prescription F1 includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 24.39%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00% and magnesium stearate 1.00%; The F2 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 21.39%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00%, hydroxypropyl cellulose 3.00% and magnesium stearate 1.00%; The F3 prescription includes the following percentage raw materials: MG raw material drug 20.83%, lactose 48.78%, microcrystalline cellulose 23.89%, sodium hydroxymethyl starch 3.00%, silicon dioxide 2.00% and magnesium stearate 1.5%.
2. The process for preparing the low-cost anticancer drug MG preparation according to claim 1, characterized in that: The preparation process of the F1 prescription comprises the following steps: S1. Weighing and sieving After weighing the raw materials according to the proportion, first MG raw material drug and silicon dioxide are sieved through a 50-mesh sieve together, then lactose, microcrystalline cellulose and sodium hydroxymethyl starch are sieved through a 50-mesh sieve in sequence, and magnesium stearate is sieved through a 30-mesh sieve alone; S2. Material mixing The sieved MG raw material drug, lactose, microcrystalline cellulose, sodium hydroxymethyl starch and silicon dioxide were placed in a No. 7 ziplock bag and manually shaken for 5 minutes. Then, the sieved magnesium stearate was added to the ziplock bag and manually shaken for another 3 minutes. S3. Filling The mixed powder was filled into hollow gelatin capsules and weighed using an analytical scale. The total weight of the capsules was controlled at 456 mg ± 5%.
3. The process for preparing the low-cost anticancer drug MG preparation according to claim 1, characterized in that: The preparation process of the F2 and F3 formulations comprises the following steps: S1. Weighing and sieving After weighing the F2 and F3 raw materials according to the proportion, the MG raw material drug and silicon dioxide were sieved through a 50-mesh sieve, and then lactose, microcrystalline cellulose, hydroxypropyl cellulose and sodium hydroxymethyl starch were sieved through a 50-mesh sieve in sequence, and magnesium stearate was sieved through a 30-mesh sieve alone; S2. Wet granulation after mixing The sieved materials of F2 and F3 were respectively placed in No. 7 ziplock bags and manually shaken for 5 minutes to obtain F2 main mixed powder and F3 main mixed powder. The F2 main mixed powder was then placed in a beaker, and the prescribed amount of binder solution was manually dripped into the beaker while stirring. After continuous stirring to form granules, the granules after wet granulation were wet granulated, and the size of the wet granulation sieve was 18 meshes; S3. Drying The wet granules were spread on a tray and placed in an oven for drying at 60°C. During the drying period, the moisture content of the granules was tested using a rapid moisture tester until the moisture content dropped below 1%. After the moisture content dropped below 1%, the F2 granules were dry granulated using a 24-mesh sieve. S4. Dry granulation The F3 main mixed powder prepared in S2 was placed in a dry granulator, and dry granulated at a roller pressure of 30 bar, a roller speed of 5 rpm, and a granulation speed of 100 rpm. After granulation, the powder was sieved using a sieve with an aperture of 1.0 mm. S5. Total Mixing The granules prepared by the wet method and the granules prepared by the dry method were respectively filled into hollow gelatin capsules and weighed using an analytical scale. The total weight of the capsules was controlled at 456 mg ± 5%.
